Regulus Therapeutics
RGLS
#6993
Rank
C$0.78 B
Marketcap
C$11.36
Share price
0.00%
Change (1 day)
425.55%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -C$66.2 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -C$64.3 Million a decrease over its 2023 earnings that were of -C$40.97 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -C$66.2 Million2.96%
2024 -C$64.3 Million56.97%
2023 -C$40.97 Million6.51%
2022 -C$38.46 Million2.53%
2021 -C$37.51 Million93.59%
2020 -C$19.38 Million-15.41%
2019 -C$22.91 Million-64.46%
2018 -C$64.45 Million-33.26%
2017 -C$96.56 Million-13.98%
2016 -C$0.12 Billion44.77%
2015 -C$77.55 Million-1.63%
2014 -C$78.83 Million203.6%
2013 -C$25.97 Million8.65%
2012 -C$23.9 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
C$10.71 B-16,333.32%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
C$2.16 B-3,381.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$12.98 B-19,767.29%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
C$19.63 B-29,845.51%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
C$13.77 B-20,964.39%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-C$0.16 Billion 129.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-C$0.17 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
C$0.80 B-1,313.98%๐Ÿ‡บ๐Ÿ‡ธ USA